PO.TB10.08 · 肿瘤生物学

空间域识别的跨平台验证:整合空间转录组学与多重免疫荧光揭示NSCLC中一致的肿瘤微环境结构

Cross platform validation of spatial domain identification reveals concordant tumor microenvironment architecture in NSCLC using integrated spatial transcriptomics and multiplex immunofluorescence

编号 4963 展板 20 时间 4/21 09:00–12:00 区域 Section 31 主讲 Paul Barber, PhD
分会场 Spatial Niches and Functional Boundaries within the Tumor Microenvironment 1
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Zeinab Mokhtari1, Mint Htun2, Debayan Mukherjee2, Nima Vakili1, Deon Hildebrand2, Crysthiane Ishiy2, Anna Pasto2, Sue Griffin2, Paul Barber2, Tony NG2

1GSK, Heidelberg, Germany,2GSK, Stevenage, United Kingdom

摘要 Abstract

中文摘要
背景:非小细胞肺癌(NSCLC)中肿瘤微环境(TME)的空间组织影响治疗反应,然而跨平台空间域识别的可重复性仍不明确。我们对手术切除的NSCLC标本进行空间转录组学(STx)和多重免疫荧光(mIF),以验证空间域识别并表征肺腺癌(LUAD)和鳞状细胞癌(LUSC)之间的TME结构。 方法:使用空间谱分析平台分析福尔马林固定石蜡包埋(FFPE)的NSCLC组织。STx使用Xenium平台进行,并通过TACCO基于最优传输的标签转移(从公共NSCLC单细胞RNA测序数据)进行细胞类型注释。mIF使用Leica Cell Dive平台进行。空间域识别在两个平台上独立完成:基础深度学习模型识别STx数据中的组织域,而Cell Charter方法结合转移变分自编码器(trVAE)确定mIF图像中的细胞结构。跨平台验证评估了STx与mIF模态之间空间域边界和组成的一致性。 结果:空间域识别揭示了STx与mIF平台在多个组织区室间的强一致性。转录组学识别的肿瘤上皮域与mIF中由EpCAM定义的区域重叠。癌症相关成纤维细胞(CAF)富集的基质域和三级淋巴结构(TLS)域在各模态间显示出一致的边界和组成。计算定义的空间域无需人工注释即可准确反映组织学特征。与LUAD相比,LUSC样本表现出扩大的CAF富集基质域和减少的T细胞浸润,提示两种亚型之间存在不同的免疫-基质组织。 结论:我们证明了NSCLC组织中空间域识别的稳健跨平台验证,计算方法能够准确重现跨转录组和蛋白质组模态的生物学区室。STx与mIF空间域之间的强一致性为用于TME表征的自动化组织分割方法建立了信心。空间域分析揭示了LUAD与LUSC之间不同的微环境结构,基质和免疫区室的组织存在差异。这一经过验证的空间域框架提供了一种可重复的高分辨率TME绘图方法,并可能有助于识别空间定义的生物标志物,用于NSCLC的精准治疗选择。
查看英文原文 English abstract
Background: Spatial organization of the tumor microenvironment (TME) in non-small cell lung cancer (NSCLC) influences therapeutic response, yet the reproducibility of spatial domain identification across platforms remains unclear. We performed spatial transcriptomics (STx) and multiplex immunofluorescence (mIF) on surgically resected NSCLC specimens to validate spatial domain identification and characterize TME architecture between lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC). Methods: Formalin-fixed paraffin-embedded NSCLC tissue was analyzed using spatial profiling platforms. STx was performed using Xenium platform with cell type annotation via TACCO optimal transport-based label transfer from public NSCLC single-cell RNA sequencing data. mIF was performed using Leica Cell Dive platform. Spatial domain identification was achieved independently on both platforms: foundational deep learning models identified tissue domains in STx data, while Cell Charter method with transfer variational autoencoder (trVAE) determined cellular architecture in mIF images. Cross-platform validation assessed concordance of spatial domain boundaries and composition between STx and mIF based modalities. Results: Spatial domain identification revealed strong concordance between STx and mIF platforms across multiple tissue compartments. Tumor epithelial domains identified transcriptomically overlapped with EpCAM-defined regions in mIF. Cancer-associated fibroblast (CAF)-enriched stromal and tertiary lymphoid structure (TLS) domains showed consistent boundaries and composition across modalities. Computationally-defined spatial domains accurately reflected histological features without manual annotation. LUSC samples exhibited expanded CAF-enriched stromal domains with reduced T-cell infiltration compared to LUAD, indicating distinct immune-stromal organization between subtypes. Conclusions: We demonstrate robust cross-platform validation of spatial domain identification in NSCLC tissue, with computational methods accurately recapitulating biological compartments across transcriptomic and proteomic modalities. The strong concordance between STx and mIF spatial domains establishes confidence in automated tissue segmentation approaches for TME characterization. Spatial domain analyses reveal distinct microenvironmental architectures between LUAD and LUSC, with differential organization of stromal and immune compartments. This validated spatial domain framework provides a reproducible approach for high-resolution TME mapping and may enable identification of spatially-defined biomarkers for precision therapy selection in NSCLC.
利益披露 Disclosure
Z. Mokhtari, GSK Employment. M. Htun, GSK Employment. D. Mukherjee, GSK Employment. N. Vakili, GSK, EMBL Employment. D. Hildebrand, GSK Employment. C. Ishiy, GSK Employment. A. Pasto, GSK Employment. S. Griffin, GSK Employment. P. Barber, GSK Employment. T. Ng, GSK Employment.

← 返回 AACR 2026 检索